Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
GAITHERSBURG, Md., Dec. 21, 2017 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.
| 10th Annual Biotech Showcase Presentation Details | ||
| Date: | Monday, January 8, 2018 | |
| Time: | 10:00am Pacific Time | |
| Location: | Hilton San Francisco Union Square, Franciscan A Ballroom | |
| Webcast: | https://event.webcasts.com/starthere.jsp?ei=1176122&tp_key=878f421c1b | |
Altimmune will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with Altimmune, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
Email: [email protected]
Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: [email protected]
